Communiqués Gilead Sciences, Inc. Buenos Aires S.E.

Actions

GILD

ARBCOM4601C4

Cours en clôture Buenos Aires S.E. Autres places de cotation 00:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
23 092 ^ARS	-5,30%		-0,89%	+16,80%

01/07	HOOKIPA Pharma annonce que le premier patient a été traité dans le cadre de l'étude sur le traitement du VIH	MT
01/07	HOOKIPA Pharma Inc. annonce que la première personne a reçu un dosage dans le cadre de l'essai clinique de phase 1b du HB-500 pour le traitement du VIH	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	03/07	AQ
Gilead Benefit Helps Employees Navigate Cancer Care	01/07	AQ
Gilead small molecule demonstrates strong capability for HIV prevention	21/06	AQ
Gilead Sciences : Access Planning in High Incidence, Resource Limited Countries for Lenacapavir for HIV Prevention	21/06	PU
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention	20/06	BU
Gilead and Kite Pharma Celebrates Pride Month	19/06	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit from Earlier Lines of Treatment	17/06	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	14/06	BU
Namibian First Ladies Call for New HIV Medicine	13/06	AQ
Combination therapy may hold potential for severe viral hepatitis	06/06	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	06/06	AQ
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	06/06	BU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06	AQ
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	05/06	BU
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation	04/06	PU
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	03/06	BU
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	03/06	BU
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	31/05	BU
Gilead Provides Update on Phase 3 TROPiCS-04 Study	30/05	BU
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies against Novel Targets and Target Pairs	29/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Gilead Sciences, Inc. Buenos Aires S.E.

Actions

GILD

ARBCOM4601C4

Communiqués

Filtres